CClinicalTrials.gg
RecruitingNCT05132257Updated May 6, 2023

Genetic Polymorphism and Retinopathy of Prematurity: Correlation of Clinical Presentations and Severity

An observational study in Retinopathy of Prematurity and Genetic Polymorphism, sponsored by Chang Gung Memorial Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 3 Years to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-06.

Sponsored by Chang Gung Memorial Hospital · Observational

From the registry’s dates

  • Primary completion was expected by Mar 2024, 2 years 6 months ago, but the record still lists the study as recruiting.
  • Started Apr 2021; still recruiting 5 years 5 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
3 Years to 12 Years
Sex
All
01

Study summary

Study Aim and Goals

  1. Evaluate the correlation between genetic polymorphism and ROP development
  2. To study the possibility if there are any specific genetic polymorphisms that lead to poor outcome or recurrence of ROP after treatment.
Read the detailed description

Background:

The preterm neonate, especially the low birth weight infant, is at a greater risk to develop disorders in multiple organ systems because of immaturity. Retinopathy of prematurity (ROP) is a disorder of the developing retina of low birth weight preterm infants that has the potential to lead to blindness. Although the pathogenesis and etiology of ROP remains unclear, many causative factors have been proposed. Vascular endothelial growth factor (VEGF) is an important regulator of angiogenesis in fetal life. In humans, polymorphisms in the VEGF gene have been reportedly associated with proliferative diabetic retinopathy and age-related degeneration. These retinal diseases might share the disease process of vasculopathy with ROP. Besides risk factors specifically associated with preterm birth, the activation of pro-inflammatory cytokines has been suggested to contribute to ROP development. Tumor necrosis factor (TNF)-α is one of the major cytokines in inflammation. Its expression was up-regulated in retinal neovascularization in animal models and proliferative eye diseases in humans. Many researchers suggest that TNF-α may affect retinal angiogenesis and predispose preterm infants for later development of ROP. Recent studies showed the possible correlation between ROP and polymorphism in VEGF (-460 T/C, +936 C/T, -634 G/C, and -2578 C/A), or TNF-α (-308 G/A). However, these studies focused on western populations. In our study, we will analyze the relationships among severity, treatment outcomes, and genetic polymorphism findings in ROP.

Study Aim and Goals

  1. Evaluate the correlation between genetic polymorphism and ROP development
  2. To study the possibility if there are any specific genetic polymorphisms that lead to poor outcome or recurrence of ROP after treatment.

Study Design Participants: We plan to recruit the children born at Linkou and Taipei branches of Chung Gung Memorial Hospital in 2009-2018, who are willing to undergo series of ophthalmologic examinations.

Study period: April, 2021 to March, 2024. A prospective cohort study Inclusion criteria: All children who were born at Linkou and Taipei branches of Chung Gung Memorial Hospital during the period of 2009 to 2018.

Exclusion criteria: If the parents were not willing to participate the study, or the medical records were not complete, or the follow period was less than 6 months.

Estimated patients' numbers: about 500 babies/3 years Methods: Participants will receive series of ocular exams, including: cycloplegic refractions, strabismus exams, exams of intraocular pressure, slit lamp exam, fundus exam, axial length measurement, etc. After the parent's and the participant's agreement, we will have a blood test of 3 ml and undergo DNA collection (Oragene-DNA; DNA-Genotek, Ottawa, Canada) by study personnel. We will analyze around 10 SNPs from each of candidate genes in our study.

According to patients' previous records and images, subjects will be classified as cases and controls. "Cases" will be infants with severe treatment-requiring ROP (defined as type-1 ROP [zone I, any stage, with plus disease; zone I, stage 3, without plus disease; or zone II, stage 2 or 3, with plus disease] or worse). "Controls" will be full-term babies without other retinal disorder, infants with no ROP or with mild ROP less severe than type-1 ROP, who are within the same birth weight group (e.g., \<1000 grams or ≥1000 grams). After matching genetic results and structural outcomes, we will analyze whether any specific genetic polymorphism had higher presentations in treatment-requiring ROP patients. Also, secondary analysis will focus on the difference between recurrent/poor outcome cases and other cases.

Statistical Analysis: Continuous variables will be analyzed with independent-t or paired-t test. One-way ANOVA will be used to compare three or more groups. Ordinal variables will be analyzed with Wilcoxon rank sum test (two independent samples) or Wilcoxon signed rank test (tow paired samples). Categorical variables will be analyzed with Chi-square test or Fisher's exact test. A multivariable logistic regression model will be constructed to assess the association between myopia prevalence and all studied risk factors. P value \<0.05 will be considered statistically significant.

02

Conditions studied

  • Retinopathy of Prematurity
  • Genetic Polymorphism

Keywords

  • Retinopathy of prematurity, genetic polymorphism
03

In context

Retinal Diseases

815 studies on the registry are indexed under Retinal Diseases; 105 are open to participants now.

This study's planned enrollment of 500 is above the median of 180 across 282 observational studies indexed under Retinal Diseases.

Browse Retinal Diseases studies →

Lead sponsor

Chang Gung Memorial Hospital is the lead sponsor of 1,064 studies on the registry; 235 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

We recruit the children born at Linkou and Taipei branches of Chung Gung Memorial Hospital in the study period, who are willing to undergo series of ophthalmologic examination

Inclusion criteria

  1. Infants born at Linkou and Taipei branches of Chang Gung Memorial Hospital during the study period.

Exclusion criteria

Exclusion Criteria:

  1. Parents unwilling to participate in the study
  2. Incomplete medical records.
  3. Folllow-up period less than 6 months
  4. Other ocular diagnosis including glaucoma, cataract, FEVR, etc.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Target follow-up
3 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • PM No-ROP

    Premature without retinopathy of prematurity. Prematurity was defined as birth at \< 37 weeks gestation.

  • Mild ROP

    Prematurity with mild retinopathy of prematurity. ROP not needing treatment. Prematurity was defined as birth at \< 37 weeks gestation.

  • Severe ROP

    Prematurity with type 1 retinopathy of prematurity. Prematurity was defined as birth at \< 37 weeks gestation.

    Procedure: Severe ROP

  • Fullterm

    Heathal fullterm.

Interventions

  • ProcedureSevere ROP

    The treatment for ROP was either primary intravitreal injection (IVI) of anti-vascular endothelial growth factor (anti-VEGF) or laser photocoagulation or vitrectomy, and the indication for treatment was type 1 ROP, as defined by the ETROP Study.

    Also known as: Type 1 ROP

06

What researchers measure

Primary outcomes

  1. SNP Selection, Detection, and Genotyping

    We will analyze around 10 SNPs from each of 53 candidate genes in our study population. Genotyping of 500 selected SNPs will be performed by TaqMan genotyping assays (Applied Biosystems, Foster City, CA) on the 7900HT Fast Real-Time PCR System (384-well platform). Primary outcome comprises frequency of mutations in percentage ratio and risk profile analysis (odds ratio).

    Time frame: 2021-2024

07

Study locations

1 of 1 sites recruiting
  • Department of Ophthalmology, Chang Gung Memorial Hospital.
    Linkou, Taoyuan 33305, Taiwan
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05132257
Lead sponsor
Chang Gung Memorial Hospital
Responsible party
Sponsor
First posted
Nov 24, 2021
Start date
Apr 12, 2021
Primary completion
Mar 31, 2024 (estimated)
Completion
Mar 31, 2024 (estimated)
Last update
May 6, 2023

Study contacts

Wu WeiChi, M.D., PhD.
Contact
weichi666@gmail.com
886-3-3281200 ext. 8666
Wu WeiChi, M.D., PhD.
principal investigator · Chang Gung Memorial Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion